{"nctId":"NCT01431287","briefTitle":"Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2011-09"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"count":2539,"armGroups":[{"label":"tiotropium+olodaterol high dose FDC","type":"EXPERIMENTAL","interventionNames":["Drug: tiotropium + olodaterol","Device: Respimat"]},{"label":"tiotropium+olodaterol low dose FDC","type":"EXPERIMENTAL","interventionNames":["Drug: tiotropium + olodaterol","Device: Respimat"]},{"label":"olodaterol","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: olodaterol","Device: Respimat"]},{"label":"tiotropium low dose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: tiotropium","Device: Respimat"]},{"label":"tiotropium high dose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: tiotropium","Device: Respimat"]}],"interventions":[{"name":"tiotropium + olodaterol","otherNames":[]},{"name":"tiotropium + olodaterol","otherNames":[]},{"name":"tiotropium","otherNames":[]},{"name":"tiotropium","otherNames":[]},{"name":"olodaterol","otherNames":[]},{"name":"Respimat","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Diagnosis of chronic obstructive pulmonary disease.\n2. Relatively stable airway obstruction with post FEV1\\< 80% predicted normal and post FEV1/FVC \\<70%.\n3. Male or female patients, 40 years of age or older.\n4. Smoking history of more than 10 pack years.\n\nExclusion criteria:\n\n1. Significant disease other than COPD\n2. Clinically relevant abnormal lab values.\n3. History of asthma.\n4. Diagnosis of thyrotoxicosis\n5. Diagnosis of paroxysmal tachycardia\n6. History of myocardial infarction within 1 year of screening visit\n7. Unstable or life-threatening cardiac arrhythmia.\n8. Hospitalization for heart failure within the past year.\n9. Known active tuberculosis.\n10. Malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years\n11. History of life-threatening pulmonary obstruction.\n12. History of cystic fibrosis.\n13. Clinically evident bronchiectasis.\n14. History of significant alcohol or drug abuse.\n15. Thoracotomy with pulmonary resection\n16. Oral ß-adrenergics.\n17. Oral corticosteroid medication at unstable doses\n18. Regular use of daytime oxygen therapy for more than one hour per day\n19. Pulmonary rehabilitation program in the six weeks prior to the screening visit\n20. Investigational drug within one month or six half lives (whichever is greater) prior to screening visit\n21. Known hypersensitivity to ß-adrenergic drugs, anticholinergics, BAC, EDTA\n22. Pregnant or nursing women.\n23. Women of childbearing potential not using a highly effective method of birth control\n24. Patients who are unable to comply with pulmonary medication restrictions","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169","description":"FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres. FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).\n\nThe adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom. Number of participants analyzed are the number of patients contributing to the MMRM model in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.136","spread":"0.009"},{"groupId":"OG001","value":"0.125","spread":"0.009"},{"groupId":"OG002","value":"0.165","spread":"0.009"},{"groupId":"OG003","value":"0.256","spread":"0.009"},{"groupId":"OG004","value":"0.268","spread":"0.009"}]}]}]},{"type":"PRIMARY","title":"Trough FEV1 Response on Day 170","description":"Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours) and was calculated as the mean of the 2 FEV1 measurements performed at 23 h and at 23 h 50 min after inhalation of study medication at the clinic visit on the previous day.\n\nTrough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).\n\nThe adjusted means (SE) were obtained from fitting an MMRM including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.057","spread":"0.009"},{"groupId":"OG001","value":"0.062","spread":"0.009"},{"groupId":"OG002","value":"0.096","spread":"0.009"},{"groupId":"OG003","value":"0.125","spread":"0.009"},{"groupId":"OG004","value":"0.145","spread":"0.009"}]}]}]},{"type":"PRIMARY","title":"Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).","description":"The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.366","spread":"0.396"},{"groupId":"OG001","value":"37.792","spread":"0.390"},{"groupId":"OG002","value":"37.907","spread":"0.393"},{"groupId":"OG003","value":"37.335","spread":"0.385"},{"groupId":"OG004","value":"36.674","spread":"0.386"}]}]}]},{"type":"SECONDARY","title":"Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)","description":"Mahler Transitional Dyspnoea Index (TDI) focal score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274) is the key secondary endpoint.\n\nThe Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.564","spread":"0.096"},{"groupId":"OG001","value":"1.690","spread":"0.095"},{"groupId":"OG002","value":"1.627","spread":"0.096"},{"groupId":"OG003","value":"1.980","spread":"0.095"},{"groupId":"OG004","value":"1.983","spread":"0.095"}]}]}]},{"type":"SECONDARY","title":"FEV1 AUC(0-3h) Response on Day 1","description":"FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.\n\nFEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.\n\nThe adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.196","spread":"0.009"},{"groupId":"OG001","value":"0.135","spread":"0.009"},{"groupId":"OG002","value":"0.164","spread":"0.009"},{"groupId":"OG003","value":"0.228","spread":"0.009"},{"groupId":"OG004","value":"0.229","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"FEV1 AUC(0-3h) Response on Day 85","description":"FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.\n\nFEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.\n\nThe adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.153","spread":"0.009"},{"groupId":"OG001","value":"0.165","spread":"0.009"},{"groupId":"OG002","value":"0.187","spread":"0.009"},{"groupId":"OG003","value":"0.272","spread":"0.009"},{"groupId":"OG004","value":"0.297","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"FEV1 AUC(0-3h) Response on Day 365","description":"FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.\n\nFEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.\n\nThe adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.105","spread":"0.010"},{"groupId":"OG001","value":"0.105","spread":"0.010"},{"groupId":"OG002","value":"0.124","spread":"0.010"},{"groupId":"OG003","value":"0.223","spread":"0.009"},{"groupId":"OG004","value":"0.237","spread":"0.010"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response on Day 15","description":"Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.\n\nTrough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.083","spread":"0.009"},{"groupId":"OG001","value":"0.085","spread":"0.009"},{"groupId":"OG002","value":"0.112","spread":"0.009"},{"groupId":"OG003","value":"0.147","spread":"0.009"},{"groupId":"OG004","value":"0.148","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response on Day 43","description":"Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.\n\nTrough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.070","spread":"0.009"},{"groupId":"OG001","value":"0.085","spread":"0.009"},{"groupId":"OG002","value":"0.103","spread":"0.009"},{"groupId":"OG003","value":"0.146","spread":"0.009"},{"groupId":"OG004","value":"0.150","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response on Day 85","description":"Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.\n\nTrough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.047","spread":"0.009"},{"groupId":"OG001","value":"0.081","spread":"0.009"},{"groupId":"OG002","value":"0.088","spread":"0.009"},{"groupId":"OG003","value":"0.129","spread":"0.009"},{"groupId":"OG004","value":"0.147","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response on Day 169","description":"Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.\n\nTrough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.034","spread":"0.009"},{"groupId":"OG001","value":"0.041","spread":"0.009"},{"groupId":"OG002","value":"0.068","spread":"0.009"},{"groupId":"OG003","value":"0.111","spread":"0.009"},{"groupId":"OG004","value":"0.119","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"Trough FEV1 Response on Day 365","description":"Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.\n\nTrough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.011","spread":"0.009"},{"groupId":"OG001","value":"0.022","spread":"0.009"},{"groupId":"OG002","value":"0.040","spread":"0.009"},{"groupId":"OG003","value":"0.077","spread":"0.009"},{"groupId":"OG004","value":"0.093","spread":"0.009"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 1","description":"FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.\n\nFVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC.Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).\n\nThe adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.","paramType":"MEDIAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.341","spread":"0.018"},{"groupId":"OG001","value":"0.264","spread":"0.018"},{"groupId":"OG002","value":"0.298","spread":"0.018"},{"groupId":"OG003","value":"0.411","spread":"0.018"},{"groupId":"OG004","value":"0.397","spread":"0.018"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 85","description":"FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.\n\nFVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC.Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).\n\nThe adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.","paramType":"MEDIAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.250","spread":"0.018"},{"groupId":"OG001","value":"0.306","spread":"0.018"},{"groupId":"OG002","value":"0.326","spread":"0.018"},{"groupId":"OG003","value":"0.460","spread":"0.018"},{"groupId":"OG004","value":"0.469","spread":"0.018"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 169","description":"FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.\n\nFVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).\n\nThe adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.","paramType":"MEDIAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.231","spread":"0.018"},{"groupId":"OG001","value":"0.247","spread":"0.018"},{"groupId":"OG002","value":"0.283","spread":"0.018"},{"groupId":"OG003","value":"0.439","spread":"0.018"},{"groupId":"OG004","value":"0.429","spread":"0.018"}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 365","description":"FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.\n\nFVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).\n\nThe adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.","paramType":"MEDIAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.180","spread":"0.019"},{"groupId":"OG001","value":"0.216","spread":"0.018"},{"groupId":"OG002","value":"0.198","spread":"0.019"},{"groupId":"OG003","value":"0.397","spread":"0.018"},{"groupId":"OG004","value":"0.381","spread":"0.019"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response on Day 15","description":"Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.\n\nTrough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.\n\nThe adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.163","spread":"0.018"},{"groupId":"OG001","value":"0.209","spread":"0.018"},{"groupId":"OG002","value":"0.222","spread":"0.018"},{"groupId":"OG003","value":"0.293","spread":"0.018"},{"groupId":"OG004","value":"0.285","spread":"0.018"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response on Day 43","description":"Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.\n\nTrough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.\n\nThe adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.129","spread":"0.018"},{"groupId":"OG001","value":"0.206","spread":"0.018"},{"groupId":"OG002","value":"0.222","spread":"0.018"},{"groupId":"OG003","value":"0.281","spread":"0.018"},{"groupId":"OG004","value":"0.293","spread":"0.018"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response on Day 85","description":"Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.\n\nTrough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.\n\nThe adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.063","spread":"0.018"},{"groupId":"OG001","value":"0.178","spread":"0.018"},{"groupId":"OG002","value":"0.184","spread":"0.018"},{"groupId":"OG003","value":"0.246","spread":"0.018"},{"groupId":"OG004","value":"0.274","spread":"0.019"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response on Day 170","description":"Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours) and was calculated as the mean of the 2 FVC measurements performed at 23h and at 23h 50 min after inhalation of study medication at the clinic visit on the previous day.\n\nTrough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).\n\nThe adjusted means (SE) were obtained from fitting an MMRM including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.116","spread":"0.018"},{"groupId":"OG001","value":"0.163","spread":"0.018"},{"groupId":"OG002","value":"0.202","spread":"0.018"},{"groupId":"OG003","value":"0.266","spread":"0.018"},{"groupId":"OG004","value":"0.274","spread":"0.018"}]}]}]},{"type":"SECONDARY","title":"Trough FVC Response on Day 365","description":"Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.\n\nTrough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.\n\nThe adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.028","spread":"0.019"},{"groupId":"OG001","value":"0.096","spread":"0.019"},{"groupId":"OG002","value":"0.097","spread":"0.019"},{"groupId":"OG003","value":"0.198","spread":"0.019"},{"groupId":"OG004","value":"0.184","spread":"0.019"}]}]}]},{"type":"SECONDARY","title":"FEV1 AUC(0-12h) Response in Sub-set of Patients With 12-hour Pulmonary Function Test (PFT) on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)","description":"FEV1 AUC(0-12h) was calculated as the area under the FEV1- time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.\n\nFEV1 AUC(0-12h) response was defined as FEV1 AUC(0-12h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).\n\nThe adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.\n\nNumber of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.131","spread":"0.015"},{"groupId":"OG001","value":"0.109","spread":"0.016"},{"groupId":"OG002","value":"0.127","spread":"0.017"},{"groupId":"OG003","value":"0.202","spread":"0.016"},{"groupId":"OG004","value":"0.250","spread":"0.016"}]}]}]},{"type":"SECONDARY","title":"FEV1 AUC(0-24h) Response in Sub-set of Patients With 12-hour PFTs on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)","description":"FEV1 AUC(0-24h) was calculated as the area under the FEV1- time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres. FEV1 AUC(0-24h) response was defined as FEV1 AUC(0-24h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).\n\nThe adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.\n\nNumber of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.108","spread":"0.014"},{"groupId":"OG001","value":"0.083","spread":"0.015"},{"groupId":"OG002","value":"0.100","spread":"0.016"},{"groupId":"OG003","value":"0.159","spread":"0.015"},{"groupId":"OG004","value":"0.206","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"FVC AUC(0-12h) Response in Sub-set of Patients With 12-hour PFTs on Day 169 From Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)","description":"FVC AUC(0-12h) was calculated as the area under the FVC- time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.\n\nFVC AUC(0-12h) response was defined as FVC AUC(0-12h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).\n\nThe adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate. Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.227","spread":"0.029"},{"groupId":"OG001","value":"0.180","spread":"0.030"},{"groupId":"OG002","value":"0.248","spread":"0.032"},{"groupId":"OG003","value":"0.356","spread":"0.030"},{"groupId":"OG004","value":"0.388","spread":"0.031"}]}]}]},{"type":"SECONDARY","title":"FVC AUC(0-24h) Response in Sub-set of Patients With 12-hour PFTs on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)","description":"FVC AUC(0-24h) was calculated as the area under the FVC- time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres.\n\nFVC AUC(0-24h) response was defined as FVC AUC(0-24h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).\n\nThe adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.\n\nNumber of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.192","spread":"0.028"},{"groupId":"OG001","value":"0.141","spread":"0.028"},{"groupId":"OG002","value":"0.203","spread":"0.030"},{"groupId":"OG003","value":"0.297","spread":"0.029"},{"groupId":"OG004","value":"0.329","spread":"0.030"}]}]}]},{"type":"SECONDARY","title":"Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 85 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)","description":"The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.832","spread":"0.398"},{"groupId":"OG001","value":"37.821","spread":"0.397"},{"groupId":"OG002","value":"37.822","spread":"0.399"},{"groupId":"OG003","value":"37.304","spread":"0.392"},{"groupId":"OG004","value":"36.691","spread":"0.394"}]}]}]},{"type":"SECONDARY","title":"Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 365 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)","description":"The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.989","spread":"0.414"},{"groupId":"OG001","value":"37.609","spread":"0.409"},{"groupId":"OG002","value":"37.581","spread":"0.411"},{"groupId":"OG003","value":"37.553","spread":"0.403"},{"groupId":"OG004","value":"37.138","spread":"0.404"}]}]}]},{"type":"SECONDARY","title":"Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 43 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)","description":"Mahler TDI focal score on Day 43 From the two twin trials, present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).\n\nThe Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.453","spread":"0.096"},{"groupId":"OG001","value":"1.430","spread":"0.097"},{"groupId":"OG002","value":"1.408","spread":"0.097"},{"groupId":"OG003","value":"1.876","spread":"0.096"},{"groupId":"OG004","value":"2.048","spread":"0.096"}]}]}]},{"type":"SECONDARY","title":"Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 85 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)","description":"Mahler TDI focal score on Day 85 From the two twin trials, present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).\n\nThe Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.506","spread":"0.097"},{"groupId":"OG001","value":"1.698","spread":"0.097"},{"groupId":"OG002","value":"1.702","spread":"0.097"},{"groupId":"OG003","value":"1.925","spread":"0.096"},{"groupId":"OG004","value":"2.136","spread":"0.096"}]}]}]},{"type":"SECONDARY","title":"Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 365 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)","description":"Mahler TDI focal score on Day 365 From the two twin trials, present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).\n\nThe Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.\n\nNumber of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.411","spread":"0.101"},{"groupId":"OG001","value":"1.450","spread":"0.100"},{"groupId":"OG002","value":"1.736","spread":"0.101"},{"groupId":"OG003","value":"1.782","spread":"0.099"},{"groupId":"OG004","value":"2.058","spread":"0.099"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":106,"n":510},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Upper respiratory tract infection","Cough","Dyspnoea"]}}}